000182763 001__ 182763
000182763 005__ 20240229145730.0
000182763 0247_ $$2doi$$a10.1002/cjp2.304
000182763 0247_ $$2pmid$$apmid:36424650
000182763 0247_ $$2altmetric$$aaltmetric:138941517
000182763 037__ $$aDKFZ-2022-02903
000182763 041__ $$aEnglish
000182763 082__ $$a610
000182763 1001_ $$0P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aAlwers, Elizabeth$$b0$$eFirst author$$udkfz
000182763 245__ $$aValidation of the prognostic value of CD3 and CD8 cell densities analogous to the Immunoscore® by stage and location of colorectal cancer: an independent patient cohort study.
000182763 260__ $$aChichester$$bWiley$$c2023
000182763 3367_ $$2DRIVER$$aarticle
000182763 3367_ $$2DataCite$$aOutput Types/Journal article
000182763 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1675695324_31406
000182763 3367_ $$2BibTeX$$aARTICLE
000182763 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182763 3367_ $$00$$2EndNote$$aJournal Article
000182763 500__ $$a#EA:C070#LA:C070# / 2023 Mar;9(2):129-136
000182763 520__ $$aIn addition to the traditional staging system in colorectal cancer (CRC), the Immunoscore® has been proposed to characterize the level of immune infiltration in tumor tissue and as a potential prognostic marker. The aim of this study was to examine and validate associations of an immune cell score analogous to the Immunoscore® with established molecular tumor markers and with CRC patient survival in a routine setting. Patients from a population-based cohort study with available CRC tumor tissue blocks were included in this analysis. CD3+ and CD8+ tumor infiltrating lymphocytes in the tumor center and invasive margin were determined in stained tumor tissue slides. Based on the T-cell density in each region, an immune cell score closely analogous to the concept of the Immunoscore® was calculated and tumors categorized into IS-low, IS-intermediate, or IS-high. Logistic regression models were used to assess associations between clinicopathological characteristics with the immune cell score, and Cox proportional hazards models to analyze associations with cancer-specific, relapse-free, and overall survival. From 1,535 patients with CRC, 411 (27%) had IS-high tumors. Microsatellite instability (MSI-high) was strongly associated with higher immune cell score levels (p < 0.001). Stage I-III patients with IS-high had better CRC-specific and relapse-free survival compared to patients with IS-low (hazard ratio [HR] = 0.42 [0.27-0.66] and HR = 0.45 [0.31-0.67], respectively). Patients with microsatellite stable (MSS) tumors and IS-high had better survival (HRCSS = 0.60 [0.42-0.88]) compared to MSS/IS-low patients. In this population-based cohort of CRC patients, the immune cell score was significantly associated with better patient survival. It was a similarly strong prognostic marker in patients with MSI-high tumors and in the larger group of patients with MSS tumors. Additionally, this study showed that it is possible to implement an analogous immune cell score approach and validate the Immunoscore® using open source software in an academic setting. Thus, the Immunoscore® could be useful to improve the traditional staging system in colon and rectal cancer used in clinical practice.
000182763 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000182763 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182763 650_7 $$2Other$$acolorectal cancer
000182763 650_7 $$2Other$$aimmune infiltration
000182763 650_7 $$2Other$$amicrosatellite instability
000182763 650_7 $$2Other$$asurvival
000182763 7001_ $$aKather, Jakob N$$b1
000182763 7001_ $$0P:(DE-He78)028ee60cca729028708496826f077b58$$aKloor, Matthias$$b2$$udkfz
000182763 7001_ $$aBrobeil, Alexander$$b3
000182763 7001_ $$aTagscherer, Katrin E$$b4
000182763 7001_ $$aRoth, Wilfried$$b5
000182763 7001_ $$aEchle, Amelie$$b6
000182763 7001_ $$0P:(DE-He78)6e02c183f41e45a5867dec393fb4616a$$aAmitay, Efrat$$b7
000182763 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b8$$udkfz
000182763 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b9$$udkfz
000182763 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b10$$eLast author$$udkfz
000182763 773__ $$0PERI:(DE-600)2814357-7$$a10.1002/cjp2.304$$gp. cjp2.304$$n2$$p129-136$$tThe journal of pathology: clinical research$$v9$$x2056-4538$$y2023
000182763 909CO $$ooai:inrepo02.dkfz.de:182763$$pVDB
000182763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000182763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)028ee60cca729028708496826f077b58$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000182763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6e02c183f41e45a5867dec393fb4616a$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000182763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000182763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000182763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000182763 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000182763 9141_ $$y2022
000182763 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ$$d2021-06-15
000182763 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-06-15
000182763 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-06-15
000182763 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-06-15
000182763 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-06-15
000182763 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-04-16T15:13:41Z
000182763 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-04-16T15:13:41Z
000182763 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2021-04-16T15:13:41Z
000182763 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ PATHOL CLIN RES : 2022$$d2023-10-26
000182763 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000182763 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000182763 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000182763 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000182763 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000182763 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-26
000182763 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-26
000182763 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000182763 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000182763 9201_ $$0I:(DE-He78)F210-20160331$$kF210$$lKKE Angewandte Tumorbiologie$$x1
000182763 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x2
000182763 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000182763 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x4
000182763 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000182763 980__ $$ajournal
000182763 980__ $$aVDB
000182763 980__ $$aI:(DE-He78)C070-20160331
000182763 980__ $$aI:(DE-He78)F210-20160331
000182763 980__ $$aI:(DE-He78)C020-20160331
000182763 980__ $$aI:(DE-He78)HD01-20160331
000182763 980__ $$aI:(DE-He78)C120-20160331
000182763 980__ $$aUNRESTRICTED